

# Narayana Hrudayalaya (NARH IN)

**Q4FY26 Result  
Update**

May 27, 2026

 Estimate Change |  Target |  Reco.

## Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	BUY		BUY	
Target Price	2,250		2,150	
Sales (INR mn)	107,695	122,104	106,115	119,327
% Chng.	1.5	2.3		
EBITDA (INR mn)	22,266	26,356	21,903	25,503
% Chng.	1.7	3.3		
EPS (INR)	58.3	72.1	60.2	72.4
% Chng.	(3.2)	(0.4)		

## Key Data

NARY.BO | NARH IN

BSE Code	539551
NSE Code	NH
52-W High / Low	INR 2,371 / INR 1,564
Face Value	10
Sensex / Nifty	76,010 / 23,914
Market Cap	INR 387 bn / \$ 4,040 mn
Shares Outstanding	204.36 mn
3M Avg. Daily Value	INR 627.33 mn

## Shareholding Pattern (%)

Promoters	63.27
FIIs	9.98
Mutual Funds	7.24
Domestic Institutions	1.91
Public & Others	17.60
Promoter's Pledge (INR bn)	-

## Stock Performance (%)

	1M	3M	6M	12M
Absolute	7.0	2.2	(3.8)	6.4
Relative	7.9	10.5	8.3	15.1

## Key Financials - Consolidated

Y/e Mar	FY25	FY26	FY27E	FY28E
Sales (INR mn)	54,830	78,960	107,695	122,104
EBITDA (INR mn)	12,764	16,927	22,266	26,356
Margin (%)	23.3	21.4	20.7	21.6
PAT (INR mn)	7,977	9,370	11,928	14,740
EV (INR mn)	402,213	413,920	410,125	402,072
Total Debt (INR mn)	22,134	48,661	45,661	40,661
C&C Eq. (INR mn)	6,467	21,292	22,086	25,140
EPS (INR)	39.0	45.9	58.4	72.1
Gr. (%)	1.1	17.5	27.3	23.6
DPS (INR)	5.2	6.0	6.4	7.0
Yield (%)	0.3	0.3	0.3	0.4
RoE (%)	24.5	23.0	23.5	23.5
RoCE (%)	19.6	16.3	16.8	18.8
EV/Sales (x)	7.3	5.2	3.8	3.3
EV/EBITDA (x)	31.5	24.5	18.4	15.3
PE (x)	48.5	41.3	32.4	26.2
P/BV (x)	10.7	8.5	6.9	5.6

## India margins to sustain

### Quick Pointers

- Guided for FY27 capex of INR30bn; greenfield capex to be at INR4.6bn
- Cayman - Incremental growth to be driven by rising patient inflows from other Caribbean islands

Narayana Hrudayalaya (NARH) reported strong EBITDA of INR5.1bn (up 43% YoY), 7% above PLe, led by another quarter of robust performance across India and Cayman operations along with the consolidation of UK subsidiary. The management reiterated its aggressive capex plan and commitment toward growing throughput over the next 3-4 years through debottlenecking, refurbishment and better bed mix. In the medium term, NARH intends to add ~1,535 beds over the next 3 years through greenfield and brownfield expansion across Bengaluru, Kolkata and Raipur. Our FY27E and FY28E EBITDA stands increased by 2-3%. We maintain 'BUY' rating with TP of INR2,250/share, based on 23x EV/EBITDA for India business and 15x EV/EBITDA for international operations based on FY28E.

**EBITDA beat driven by strong growth across India and Cayman businesses:** NARH reported EBITDA of INR5.1bn (up 43% YoY) vs. PLe of INR4.8bn. Growth was aided by UK subsidiary consolidation, which reported revenue of INR8.1bn and post IND-AS EBITDA of INR845mn with OPM at 10.4% (up 200bps QoQ). Consol margin stood at 19.7% (down ~460bps YoY). Q4 losses in India insurance and clinics business increased to INR181mn vs. INR134mn in Q3, while total loss for FY26 stood at INR672mn vs. INR645mn in FY25. Losses from Cayman Integrated Healthcare (CIHL) increased sharply to US\$5.1mn in Q4 vs. US\$1.5mn in Q3. India business, adjusted for insurance and clinics, reported EBITDA of INR2.91bn, up ~35% YoY. India margins improved by ~400bps YoY to 23.6%. Cayman EBITDA, adjusted for CIHL, came in at US\$22mn, up 20% YoY and 4% QoQ, with OPM of ~45%.

**Healthy ARPOB growth aided by better case mix:** Revenue grew by 76% YoY to INR26bn. ARPOB for India business grew 10% YoY to INR51k/day led by better payor mix. IP volumes were up 2% YoY and flat QoQ for India due to capacity constraints in existing hospitals. Cayman revenue excluding insurance business increased 13% YoY to US\$50mn. Both IP and OP volumes for Cayman improved by ~5% and ~10% YoY, respectively. Reported PAT stood at INR2.28bn (up ~16% YoY). NARH's net debt was largely flat QoQ to INR22.4bn.

### Quarter Summary

Y/e Mar	Q4'26E	Q4'26A	% Var.	Q4'25A	YoY gr. (%)
Net Sales (INR mn)	25,328	25,938	2.0	14,754	76.0
EBITDA (INR mn)	4,786	5,100	7.0	3,577	43.0
Margin (%)	18.9	19.7	80 bps	24.2	-450 bps
PAT (INR mn)	2,454	2,281	-7.0	2,046	11.0

Source: Company, PL

## Conference Call Highlights

**Bed expansion plan:** NARH is now entering a major expansion cycle, with greenfield projects across Rajarhat (Kolkata), HSR Layout (Bengaluru), Raipur, and a second Bengaluru facility, all expected to be commissioned by FY28. The Rajarhat project is strategically important as it will create an integrated quaternary care facility and address scalability constraints of the existing Kolkata campus, which currently operates only ~30% of Bengaluru's bone marrow transplant bed capacity.

**Capex outlook and guidance for FY27:** FY26 greenfield capex stood at INR1.1bn (earlier guided at INR4.24bn), due to election-led labor shortages and approval delays. However, the management has guided that FY28 commissioning timelines remain intact, with execution expected to accelerate going forward. Total domestic capex is guided at ~INR30bn, alongside ~INR4.6bn for greenfield inorganic opportunities, with commissioning across FY28–29, implying annual spend of ~INR10bn during the period.

**India hospitals:** Margins expansion was driven by payer mix optimization, higher contribution from complex quaternary care, and operational transformation initiatives. The Bengaluru cluster remains the key growth driver, with ARPP exceeding INR250k, supported by leadership in robotic cardiac surgeries, percutaneous aortic valve procedures, and pediatric bone marrow transplants. The slower 5%–6% growth in the Kolkata cluster in FY26 was attributed to reduced international patient contribution. The company continues to focus on ARPP over occupancy metrics, typically operating at 60%–65% occupancy. Meanwhile, Mumbai's SRCC Children's Hospital achieved EBITDA breakeven in Q4, while the proposed adult care expansion remains under advanced discussions and is guided to materially improve profitability. In the northern cluster, the management continues to focus on Dharamshila and Gurugram. The cluster's 5%–7% FY26 growth was attributed to structural market dynamics.

**India hospitals' margin guidance:** Management believes margin gains are largely sustainable, though input cost inflation, macro volatility, and greenfield ramp-up losses from FY27 could create near-term pressure.

**India clinics:** NARH operates 11 clinics in Bengaluru and plans to double the network, including entry into Kolkata in FY27, while maintaining disciplined expansion and cash burn control. From FY27, clinic financials will be merged into the core hospital P&L, reflecting shared medical resources and referral flows. NHIC & NHIL reported a combined FY26 loss of ~INR660mn, flat YoY, largely reflecting corporate overheads and the ramp-up costs of newer clinics, rather than underlying operating weakness.

**Cayman business:** Quarterly revenue improved from <USD35mn in Q3FY25 to ~USD65mn in Q4FY26, driven by the Camana Bay ramp-up and the integrated One Health model enhancing insurance-led patient steerage. The management reiterated that hospital and insurance operations should be viewed as a single integrated ecosystem, rather than standalone entities.

**Cayman guidance:** Growth is expected to moderate as the Cayman market is relatively small, though margins have remained stable through the transition to Camana Bay. Incremental upside is emerging from rising patient inflows from other Caribbean islands, which the management sees as the next major growth driver as domestic opportunity matures. CIHL reported ~USD5mn quarterly loss, expects sequential improvement over the next 3 quarters, supported by Jun'26 price increases across 30%–35% of accounts and renewal-led repricing/exits of underpriced risks, though 1–2 more quarters of similar losses are likely.

**Practice Plus (UK clinics):** Reported EBITDA margin improved to ~10% in Q4 vs. 7%–8% at acquisition, though the management has cautioned that near-term trends are not directly comparable due to mid-quarter closing, integration and transition costs, incomplete IT separation, and expense reclassifications. NARH's focus is on deploying the Atma platform to drive efficiency in the fragmented UK system, increasing private/self-pay mix (~7% at entry), and replicating the Cayman integrated care model.

On a normalized basis, margins are guided at ~22% (adjusted for UK subsidiary acquisition-related costs).

**Exhibit 1 : Q4FY26 Result Overview (INR mn) – Another strong quarter across India and Cayman businesses**

(INR mn)	4QFY26	4QFY25	YoY gr. (%)	4QFY26E	% Var.	3QFY26	QoQ gr. (%)	FY26	FY25	YoY gr. (%)
Net Sales	25,938	14,754	75.8	25,328	2.4	21,512	20.6	78,960	54,830	44.0
COGS	5,066	3,053	65.9	7,142	(29.1)	3,815	32.8	15,161	11,364	33.4
% of Net Sales	19.5	20.7		28.2		17.7		19.2	20.7	
Employee Cost	7,489	2,754	171.9	1,916	290.8	5,387	39.0	18,030	10,927	65.0
% of Net Sales	28.9	18.7		7.6		25.0		22.8	19.9	
Other Expenses	8,283	5,370	54.2	11,484	(27.9)	7,878	5.1	29,603	19,775	49.7
% of Net Sales	31.9	36.4		45.3		36.6		37.5	36.1	
<b>Total</b>	<b>20,838</b>	<b>11,177</b>	<b>86.4</b>	<b>20,542</b>	<b>1.4</b>	<b>17,079</b>	<b>22.0</b>	<b>62,794</b>	<b>42,066</b>	<b>49.3</b>
<b>EBITDA</b>	<b>5,100</b>	<b>3,577</b>	<b>42.6</b>	<b>4,786</b>	<b>6.6</b>	<b>4,432</b>	<b>15.1</b>	<b>16,167</b>	<b>12,764</b>	<b>26.7</b>
Margins (%)	19.7	24.2		18.9		20.6		20.5	23.3	
Other Income	292	268	8.9	190	53.8	232	26.0	1,002	920	8.9
Interest	913	407	124.4	664	37.4	650	40.4	2,437	1,464	66.5
Depreciation	1,538	825	86.4	1,217	26.3	1,223	25.8	4,478	2,781	61.0
<b>PBT</b>	<b>2,942</b>	<b>2,614</b>	<b>12.5</b>	<b>3,095</b>	<b>(4.9)</b>	<b>2,792</b>	<b>5.4</b>	<b>10,253</b>	<b>9,439</b>	<b>8.6</b>
Tax	641	568	12.9	627	2.3	223	187.9	1,584	1,457	8.7
Tax rate %	21.8	21.7		20.2		8.0		15.4	15.4	
<b>PAT</b>	<b>2,300</b>	<b>2,046</b>	<b>12.4</b>	<b>2,468</b>	<b>(6.8)</b>	<b>2,569</b>	<b>(10.4)</b>	<b>8,670</b>	<b>7,982</b>	<b>8.6</b>
Share in (loss)/profit of associate	(20)	-		(14)	40.8	(19)		(56)	-	NA
EO items	(0)	(84)		-	NA	(509)		(510)	(83.6)	509.3
Minority Interest	-	-		-	NA	-		(4)	(4.8)	(20.2)
<b>Reported PAT</b>	<b>2,280</b>	<b>1,962</b>	<b>16.2</b>	<b>2,454</b>	<b>(7.1)</b>	<b>2,041</b>	<b>11.7</b>	<b>8,101</b>	<b>7,893</b>	<b>2.6</b>

Source: Company, PL

**Exhibit 2 : Break-up of revenue**

Revenue (INR mn)	4QFY26	4QFY25	YoY gr. (%)	3QFY26	QoQ gr. (%)	FY26	FY25	YoY gr. (%)
Cayman	4,314	3,797	13.6	3,864	11.6	15,204	11,829	28.5
CIHL	1,304	-	-	1,127	15.7	3,689	-	
India hospitals	12,170	10,830	12.4	11,468	6.1	46,702	42,818	9.1
India Clinics	162	123	31.7	156	3.8	609	329	85.1
Practice Plus- UK	8,090	-	-	4,902	65.0	12,992	-	
<b>Total Sales</b>	<b>26,040</b>	<b>14,750</b>	<b>76.5</b>	<b>21,517</b>	<b>21.0</b>	<b>79,196</b>	<b>54,976</b>	<b>44.1</b>


Source: Company, PL

**Exhibit 3 : Break-up of EBITDA**

EBITDA (INR mn)	4QFY26	4QFY25	YoY gr. (%)	3QFY26	QoQ gr. (%)	FY26	FY25	YoY gr. (%)
Cayman	1,995	1,540	29.5	1,847	8.0	6,935	5,054	37.2
% OPM	46.3%	40.6%		47.8%		45.6%	42.7%	
CHIL	(465)	-		(131)	255.0	(715)		
India	2,906	2,156	34.8	2,430	19.6	10,158	8,246	23.2
% OPM	23.6%	19.9%		21.2%		23.7%	19.3%	
NHIC and NHIL	(181)	(242)	25.3	(134)	(35.1)	(672)	(645)	(4.3)
Practice Plus - UK	845	-		420		1,265	-	
% OPM	10.4%	NA		8.6%		9.7%		
<b>Total EBITDA</b>	<b>5,100</b>	<b>3,454</b>	<b>47.6</b>	<b>4,432</b>	<b>15.1</b>	<b>16,971</b>	<b>12,655</b>	


Source: Company, PL

**Exhibit 4: Consolidated OPM declined by ~460bps YoY**




Source: Company, PL

**Exhibit 5: India margins adj for NHC losses improved by ~400bps YoY**




Source: Company, PL

**Exhibit 6: Cayman EBITDA grew at ~30% YoY adj for CIHL losses**




Source: Company, PL

Exhibit 7: India ARPOB increased ~10% YoY due to better payor mix




Source: Company, PL

Exhibit 8: Net debt increased by INR76mn QoQ




Source: Company, PL

Exhibit 9: Increased integrated care losses QoQ



Source: Company, PL

Exhibit 10: Cayman's insurance business losses increased sharply QoQ



Source: Company, PL

## Financials

### Income Statement (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
<b>Net Revenues</b>	<b>54,830</b>	<b>78,960</b>	<b>107,695</b>	<b>122,104</b>
YoY gr. (%)	9.3	44.0	36.4	13.4
Cost of Goods Sold	11,364	15,161	23,693	26,863
Gross Profit	43,466	63,799	84,002	95,241
Margin (%)	79.3	80.8	78.0	78.0
Employee Cost	10,927	18,030	20,554	23,432
Other Expenses	19,775	28,843	41,182	45,453
<b>EBITDA</b>	<b>12,764</b>	<b>16,927</b>	<b>22,266</b>	<b>26,356</b>
YoY gr. (%)	10.8	32.6	31.5	18.4
Margin (%)	23.3	21.4	20.7	21.6
Depreciation and Amortization	2,781	4,478	5,870	6,457
<b>EBIT</b>	<b>9,983</b>	<b>12,449</b>	<b>16,396</b>	<b>19,900</b>
Margin (%)	18.2	15.8	15.2	16.3
Net Interest	1,464	2,437	3,053	2,600
Other Income	920	1,002	1,100	1,200
<b>Profit Before Tax</b>	<b>9,439</b>	<b>11,013</b>	<b>14,443</b>	<b>18,500</b>
Margin (%)	17.2	13.9	13.4	15.2
Total Tax	1,457	1,584	2,455	3,700
Effective Tax Rate (%)	15.4	14.4	17.0	20.0
<b>Profit After Tax</b>	<b>7,982</b>	<b>9,430</b>	<b>11,988</b>	<b>14,800</b>
Minority Interest	(5)	(4)	(10)	(10)
Share Profit from Associate	-	(56)	(50)	(50)
<b>Adjusted PAT</b>	<b>7,977</b>	<b>9,370</b>	<b>11,928</b>	<b>14,740</b>
YoY gr. (%)	1.1	17.5	27.3	23.6
Margin (%)	14.5	11.9	11.1	12.1
Extra Ord. Income / (Exp)	-	-	-	-
<b>Reported PAT</b>	<b>7,893</b>	<b>8,101</b>	<b>11,928</b>	<b>14,740</b>
YoY gr. (%)	-	2.6	47.2	23.6
Margin (%)	14.4	10.3	11.1	12.1
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	7,893	8,101	11,928	14,740
<b>Equity Shares O/s (mn)</b>	<b>204</b>	<b>204</b>	<b>204</b>	<b>204</b>
<b>EPS (INR)</b>	<b>39.0</b>	<b>45.9</b>	<b>58.4</b>	<b>72.1</b>

Source: Company, PL

### Balance Sheet (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
<b>Non-Current Assets</b>				
<b>Gross Block</b>	<b>60,963</b>	<b>88,027</b>	<b>98,027</b>	<b>108,027</b>
Tangibles	58,718	79,571	89,571	99,571
Intangibles	2,245	8,456	8,456	8,456
<b>Acc: Dep / Amortization</b>	<b>19,496</b>	<b>23,974</b>	<b>29,844</b>	<b>36,300</b>
Tangibles	19,496	23,974	29,844	36,300
Intangibles	-	-	-	-
<b>Net Fixed Assets</b>	<b>41,468</b>	<b>64,053</b>	<b>68,183</b>	<b>71,726</b>
Tangibles	39,222	55,597	59,727	63,270
Intangibles	2,245	8,456	8,456	8,456
Capital Work In Progress	859	2,919	2,919	2,919
Goodwill	1,189	13,906	13,906	13,906
Non-Current Investments	10,843	5,732	5,732	5,732
Net Deferred Tax Assets	(559)	(3,195)	(3,195)	(3,195)
Other Non-Current Assets	-	-	-	-
<b>Current Assets</b>				
Investments	-	-	-	-
Inventories	1,103	1,545	2,213	2,509
Trade Receivables	5,555	6,557	9,442	11,039
Cash & Bank Balance	6,467	21,292	22,086	25,140
Other Current Assets	5,089	8,629	10,327	11,709
<b>Total Assets</b>	<b>72,650</b>	<b>124,744</b>	<b>134,920</b>	<b>144,792</b>
<b>Equity</b>				
Equity Share Capital	2,044	2,044	2,044	2,044
Other Equity	34,220	43,329	53,953	67,270
<b>Total Networkth</b>	<b>36,264</b>	<b>45,373</b>	<b>55,996</b>	<b>69,314</b>
<b>Non-Current Liabilities</b>				
Long Term Borrowings	22,134	48,661	45,661	40,661
Provisions	-	-	-	-
Other Non Current Liabilities	-	-	-	-
<b>Current Liabilities</b>				
ST Debt / Current of LT Debt	-	-	-	-
Trade Payables	5,745	10,321	12,873	14,428
Other Current Liabilities	5,704	7,145	7,145	7,145
<b>Total Equity &amp; Liabilities</b>	<b>72,650</b>	<b>124,744</b>	<b>134,920</b>	<b>144,792</b>

Source: Company, PL

**Cash Flow (INR mn)**

Y/e Mar	FY25	FY26	FY27E	FY28E
PBT	9,439	11,013	14,443	18,500
Add. Depreciation	2,781	4,478	5,870	6,457
Add. Interest	1,464	2,437	3,053	2,600
Less Financial Other Income	920	1,002	1,100	1,200
Add. Other	(1,371)	1,698	(60)	(60)
Op. Profit before WC Changes	12,313	19,627	23,306	27,496
Net Changes-WC	(1,185)	(1,849)	(2,699)	(1,721)
Direct Tax	(1,270)	(1,566)	(2,455)	(3,700)
<b>Net Cash from Op. Activities</b>	<b>9,858</b>	<b>16,212</b>	<b>18,151</b>	<b>22,076</b>
Capital Expenditures	(10,820)	(8,752)	(10,000)	(10,000)
Interest / Dividend Income	-	-	-	-
Others	(2,434)	(27,904)	-	-
<b>Net Cash from Inv. Activities</b>	<b>(13,253)</b>	<b>(36,655)</b>	<b>(10,000)</b>	<b>(10,000)</b>
Issue of Share Cap. / Premium	-	-	-	-
Debt Changes	7,942	27,263	(3,000)	(5,000)
Dividend Paid	(812)	(910)	(1,304)	(1,422)
Interest Paid	(1,464)	(2,437)	(3,053)	(2,600)
Others	33	11,353	-	-
<b>Net Cash from Fin. Activities</b>	<b>5,698</b>	<b>35,268</b>	<b>(7,357)</b>	<b>(9,022)</b>
<b>Net Change in Cash</b>	<b>2,303</b>	<b>14,824</b>	<b>794</b>	<b>3,053</b>
Free Cash Flow	(962)	7,460	8,151	12,076

Source: Company, PL

**Quarterly Financials (INR mn)**

Y/e Mar	Q1FY26	Q2FY26	Q3FY26	Q4FY26
<b>Net Revenues</b>	<b>15,073</b>	<b>16,438</b>	<b>21,512</b>	<b>25,938</b>
YoY gr. (%)	12.4	20.3	61.2	75.8
Raw Material Expenses	3,058	3,222	3,815	5,066
Gross Profit	12,015	13,216	17,697	20,872
Margin (%)	79.7	80.4	82.3	80.5
<b>EBITDA</b>	<b>3,370</b>	<b>4,069</b>	<b>4,432</b>	<b>5,100</b>
YoY gr. (%)	10.9	31.8	44.2	42.6
Margin (%)	22.4	24.8	20.6	19.7
Depreciation / Depletion	843	875	1,223	1,538
<b>EBIT</b>	<b>2,526</b>	<b>3,194</b>	<b>3,210</b>	<b>3,562</b>
Margin (%)	16.8	19.4	14.9	13.7
Net Interest	452	423	650	913
Other Income	238	240	232	292
<b>Profit before Tax</b>	<b>2,313</b>	<b>3,012</b>	<b>2,792</b>	<b>2,942</b>
Margin (%)	15.3	18.3	13.0	11.3
Total Tax	348	372	223	641
Effective Tax Rate (%)	15.0	12.4	8.0	21.8
<b>Profit After Tax</b>	<b>1,965</b>	<b>2,640</b>	<b>2,569</b>	<b>2,300</b>
Minority Interest	-	-	-	-
Share Profit from Associate	(4)	(13)	(19)	(20)
<b>Adjusted PAT</b>	<b>1,961</b>	<b>2,627</b>	<b>2,550</b>	<b>2,281</b>
YoY gr. (%)	(2.0)	31.8	31.7	11.5
Margin (%)	13.0	16.0	11.9	8.8
Extra Ord. Income / (Exp)	-	(44)	(509)	-
<b>Reported PAT</b>	<b>1,961</b>	<b>2,583</b>	<b>2,041</b>	<b>2,280</b>
YoY gr. (%)	(2.0)	29.6	5.4	16.2
Margin (%)	13.0	15.7	9.5	8.8
Other Comprehensive Income	-	-	-	-
<b>Total Comprehensive Income</b>	<b>1,961</b>	<b>2,583</b>	<b>2,041</b>	<b>2,280</b>
Avg. Shares O/s (mn)	204	204	204	204
<b>EPS (INR)</b>	<b>9.6</b>	<b>12.6</b>	<b>10.0</b>	<b>11.2</b>

Source: Company, PL

**Key Financial Metrics**


Y/e Mar	FY25	FY26	FY27E	FY28E
<b>Per Share (INR)</b>				
EPS	39.0	45.9	58.4	72.1
CEPS	52.6	67.8	87.1	103.7
BVPS	177.4	222.0	274.0	339.2
FCF	(4.7)	36.5	39.9	59.1
DPS	5.2	6.0	6.4	7.0
<b>Return Ratio (%)</b>				
RoCE	19.6	16.3	16.8	18.8
ROIC	15.1	12.0	14.5	16.6
RoE	24.5	23.0	23.5	23.5
<b>Balance Sheet</b>				
Net Debt : Equity (x)	0.4	0.6	0.4	0.2
Net Working Capital (Days)	6	(10)	(4)	(3)
<b>Valuation (x)</b>				
PER	48.4	41.2	32.4	26.2
P/B	10.6	8.5	6.9	5.5
P/CEPS	35.9	27.9	21.7	18.2
EV/EBITDA	31.5	24.4	18.4	15.2
EV/Sales	7.3	5.2	3.8	3.2
Dividend Yield (%)	0.2	0.3	0.3	0.3
FCFF Yield (%)	-	1.9	2.1	3.1
PEG Ratio	45.2	2.3	1.1	1.1

Source: Company, PL

**Key Operating Metrics**

Y/e Mar	FY25	FY26	FY27E	FY28E
India hospitals	42,300	59,367	85,395	97,104
Cayman Island	11,829	18,893	21,600	24,300
Others	700	700	700	700

Source: Company, PL

**Price Chart**

**Recommendation History**

No.	Date	Rating	TP (INR)	Share Price (INR)
1	09-Apr-26	BUY	2150	1728
2	18-Feb-26	BUY	2150	1829
3	06-Jan-26	BUY	2100	1901
4	19-Dec-25	BUY	2100	1920
5	19-Nov-25	BUY	2100	1952
6	04-Nov-25	BUY	2000	1783
7	08-Oct-25	BUY	2000	1781
8	05-Aug-25	BUY	2000	1830
9	08-Jul-25	BUY	1950	1990
10	28-May-25	BUY	1950	1743

**Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (INR)	Share Price (INR)
1	Ajanta Pharma	BUY	3400	2898
2	Anthem Biosciences	BUY	850	781
3	Apollo Hospitals Enterprise	BUY	9350	8309
4	Aster DM Healthcare	Buy	800	701
5	Aurobindo Pharma	Hold	1400	1464
6	Brigade Enterprises	Buy	1045	758
7	Cipla	Accumulate	1400	1328
8	Divi's Laboratories	Accumulate	6900	6887
9	Dr. Reddy's Laboratories	Accumulate	1400	1270
10	Eris Lifesciences	BUY	1750	1458
11	Fortis Healthcare	Buy	1120	970
12	Global Health	BUY	1450	1243
13	HealthCare Global Enterprises	BUY	820	650
14	Indoco Remedies	Hold	325	225
15	Ipca Laboratories	Buy	1800	1445
16	J.B. Chemicals & Pharmaceuticals	Buy	2400	2135
17	Jupiter Life Line Hospitals	Buy	1600	1331
18	Krishna Institute of Medical Sciences	Buy	800	717
19	Lupin	Accumulate	2500	2380
20	Max Healthcare Institute	Buy	1175	1023
21	Narayana Hrudayalaya	BUY	2150	1728
22	Oberoi Realty	Accumulate	1820	1635
23	Prestige Estates Projects	Buy	1800	1402
24	Rainbow Children's Medicare	Buy	1615	1350
25	Sun Pharmaceutical Industries	Buy	2070	1845
26	Sunteck Realty	Buy	520	356
27	Torrent Pharmaceuticals	Buy	5000	4573
28	Zydus Lifesciences	Accumulate	1080	1019

**PL's Recommendation Nomenclature (Absolute Performance)**

<b>BUY</b>	: > 15%
<b>Accumulate</b>	: 5% to 15%
<b>Hold</b>	: +5% to -5%
<b>Reduce</b>	: -5% to -15%
<b>Sell</b>	: < -15%
<b>Not Rated (NR)</b>	: No specific call on the stock
<b>Under Review (UR)</b>	: Rating likely to change shortly

## ANALYST CERTIFICATION

### Indian Clients

We/I Mr. Param Desai MBA Finance, Ms. Sanketa Kohale MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### US Clients

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

### Prabhudas Lilladher Pvt. Ltd.

**Corporate Office:** 6th Floor, Tower 2B South Annex, One World Centre, 841, Senapati Bapat Marg, Lower Parel, Mumbai - 400013

**Registered Office:** 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018

Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

[www.plindia.com](http://www.plindia.com)

## DISCLAIMER

### Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd, which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at [www.plindia.com](http://www.plindia.com).

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipients particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report.

PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report.

PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai MBA Finance, Ms. Sanketa Kohale MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

### US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.